{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T03:51:21Z","timestamp":1777866681383,"version":"3.51.4"},"reference-count":0,"publisher":"S. Karger AG","license":[{"start":{"date-parts":[[2017,8,11]],"date-time":"2017-08-11T00:00:00Z","timestamp":1502409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2017,8,11]],"date-time":"2017-08-11T00:00:00Z","timestamp":1502409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dev Pharmacol Ther"],"abstract":"<jats:p>Suppression of hyperbilirubinemia was studied in jaundiced adult and neonatal\nGunn rats following treatment with tin-protoporphyrin. The effects of tin-protoporphyrin\ntreatment on heme oxygenase, NADPH cytochrome c reductase, and biliverdin reductase\nactivities were studied in adult jaundiced Gunn rat renal, hepatic and splenic tissues.\nHepatic heme oxygenase activity was studied in nonjaundiced and jaundiced Gunn neonates.\nSignificant decreases in plasma bilirubin levels were observed for both adult and\nneonatal rats treated with 50 or 100 \u00b5mol tin-protoporphyrin\/kg body weight. Tin-protoporphyrin-\ntreated rats had significntly lower hepatic and renal heme oxygenase activities,\nsplenic and renal cytochrome c reductase activities, and a significantly higher splenic biliverdin\nreductase activity. Hepatic heme oxygenase activity was also significantly reduced in\nthe neonatal rats.<\/jats:p>","DOI":"10.1159\/000457703","type":"journal-article","created":{"date-parts":[[2017,8,11]],"date-time":"2017-08-11T17:09:02Z","timestamp":1502471342000},"page":"281-287","source":"Crossref","is-referenced-by-count":1,"title":["Tin-Protoporphyrin Suppression of Hyperbilirubinemia in the\nJaundiced Gunn Rat"],"prefix":"10.1159","author":[{"given":"David R.","family":"Davis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie P.","family":"Bail","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2017,8,11]]},"container-title":["Developmental Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000457703","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T09:09:20Z","timestamp":1777540160000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000457703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,11]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1159\/000457703","archive":["Portico"],"relation":{},"ISSN":["0379-8305","2504-2505"],"issn-type":[{"value":"0379-8305","type":"print"},{"value":"2504-2505","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,11]]}}}